Revenue + Forward P/E
Bristol-Myers Squibb Company (BMY) quarterly revenue and forward P/EForward P/E: 10.0x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$130.12B
Enterprise value
$161.68B
P/E ratio (TTM)
17.44x
P/S ratio (TTM)
2.62x
P/B ratio
6.32x
EV/Sales
3.33x
EV/EBITDA
11.76x
Dividend yield
4.04%
Income statement (TTM)
Revenue (TTM)
$48.19B
Gross profit (TTM)
$32.60B
Operating income (TTM)
$12.70B
EBITDA (TTM)
$14.54B
Net income (TTM)
$7.05B
Free cash flow (TTM)
$12.85B
Margins & returns
Gross margin
68.75%
Operating margin
25.67%
Profit margin
15.01%
Return on equity
39.05%
Return on assets
8.41%
Per-share metrics
EPS (TTM)
$3.56
Dividend yield
4.04%
Beta
0.23
Capital structure
Cash & equivalents
$10.21B
Total debt
$47.14B
Net debt
$36.93B
Shares outstanding
2.04B
Financial health
Current ratio
1.26
Debt / equity
2.55
Debt / assets
0.52
Interest coverage
8.41
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $628.65B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $439.33B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $368.33B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $357.68B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $328.31B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $130.12B | 17.44x | 2.62x | 11.76x | 4.04% |